TranS1 revenue increase not enough to save bottom line
This article was originally published in Clinica
Orthopaedics firm TranS1 saw its bottom line fall in the fourth quarter of 2008, despite witnessing strong revenues growth during the period. The Wilmington, North Carolina-based company recorded sales of around $7.4m, up 48% over Q4 2007. However, this was not enough to prevent its net loss from slipping to $4.5m, down from $2.2m for the same period last year. This was attributed to higher operating expenses – which went up 52% to $11.1m – resulting from increased sales and marketing efforts. The firm’s Q4 performance mirrored its full-year results, as revenue went up 54% to $25.3m, while net loss widened to $17.0m from $8.6m.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals